| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 4,373,400 | 4,655,600 | 4,451,600 | 4,138,700 | 5,063,300 |
| Sales Growth | -6.06% | +4.58% | +7.56% | -18.26% | +4.67% |
| Net Income | -171,800 | -12,700 | -140,600 | -68,900 | -162,600 |
| Net Income Growth | -1,252.76% | +90.97% | -104.06% | +57.63% | -211.29% |
Perrigo Company (PRGO)
20.77 x 1 40.98 x 4
Post-market by (Cboe BZX)
27.20 -0.54 (-1.95%) 03/25/25 [NYSE]
20.77 x 1 40.98 x 4
Post-market 29.08 +1.88 (+6.91%) 16:26 ET
for Tue, Mar 25th, 2025
Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International'(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business.
Fiscal Year End Date: 12/31